Sofosbuvir / Ledipasvir Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: Sofosbuvir 400 mg & Ledipasvir 90 mg
Reference Brands: Harvoni®(EU & US)
Category: Anti Viral
Sofosbuvir 400 mg and ledipasvir 90 mg tablets, a once-daily direct-acting antiviral combination for chronic hepatitis C genotypes 1, 4, 5 and 6. For hepatitis programmes, tender buyers, hospitals and importers.
Manufacture or export Sofosbuvir / Ledipasvir? List it or send an offer →
Product Description:
This tablet combines sofosbuvir 400 mg, a nucleotide analogue that blocks the hepatitis C virus NS5B polymerase, with ledipasvir 90 mg, an inhibitor of the NS5A protein the virus needs for replication and assembly. Together they form an all-oral, interferon-free regimen of one film-coated tablet a day. The fixed-dose form made this pairing practical in national hepatitis C programmes: no injections, no ribavirin for most patients, and a short, fixed course that suits decentralised care.
It is approved for chronic hepatitis C genotypes 1, 4, 5 and 6, usually for 12 weeks, with eight weeks possible in some treatment-naive patients without cirrhosis. It does not cover genotypes 2 and 3 well, which is why WHO now favours pangenotypic regimens. Ledipasvir absorption falls with acid-reducing drugs, so antacids, H2 blockers and proton pump inhibitors need careful timing. Amiodarone is a serious hazard because of severe bradycardia, and strong P-gp inducers such as rifampicin must be avoided. Screen for hepatitis B first, as it can reactivate.
Sourcing notes. Patents and voluntary licences decide where generic versions may be sold, so confirm your country is in a licensed territory, or that no blocking patent applies, before ordering. Tender buyers often need WHO prequalification or approval by a stringent regulatory authority; ask for the evidence. Request a batch CoA covering assay, dissolution and impurities of each active, along with the bioequivalence study, GMP certificate and CoPP. Tablets come in bottles with desiccant or in blisters, with zone IVb data and no cold chain. State course pack and label language.
Sofosbuvir / Ledipasvir — third party manufacturing & bulk supply
Sofosbuvir / Ledipasvir is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
Indicative minimum order quantity
Sofosbuvir / Ledipasvir is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Sofosbuvir / Ledipasvir listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.
Request a quote for Sofosbuvir / Ledipasvir →Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.
Frequently Asked Questions
Sofosbuvir & Ledipasvir is used for the treatment of chronic hepatitis C virus (HCV) infection, mainly genotype 1, 4, 5, and 6. It helps reduce viral load and supports complete viral clearance with sustained virologic response.
It is made from the active ingredients sofosbuvir, an NS5B polymerase inhibitor, and ledipasvir, an NS5A inhibitor. Together they block HCV replication and viral assembly.
The primary trade name is Harvoni in the USA, EU, and UK, along with multiple licensed generics available in India and other regions.
Harvoni is manufactured by Gilead Sciences. Several licensed generic manufacturers in India and other countries also produce approved generic versions.
The generic name is sofosbuvir & ledipasvir.
The main brand name is Harvoni, with various licensed generic brand names depending on the region.
It is manufactured by Gilead Sciences in the USA and by licensed generic manufacturers in India and other global regions.
Related Products
Ritonavir & Lopinavir
Strength:
Tab: Lopinavir 200 mg + Ritonavir 50 mg; oral solution:80 mg / 20 mg per mL
Form: Tablet and Oral Solution
Reference Brands: Kaletra(US & EU)
View DetailsTenofovir & Emtricitabine
Strength:
Tenofovir DF 300 mg + Emtricitabine 200 mg
Form: Tablet
Reference Brands: Truvada®(US/EU)
View DetailsNelfinavir Mesylate
Strength:
Tablets: 250 mg, 625 mg: Oral Powder: 50 mg/g
Form: Tablet & Oral Powder
Reference Brands: Viracept®
View DetailsAtazanavir
Strength:
150 mg, 200 mg, 300 mg
Form: Capsules
Reference Brands: Reyataz®(EU & US)
View DetailsEnfuvirtide Acetate
Strength:
90 mg/vial
Form: Injection
Reference Brands: Fuzeon (USA/EU)
View DetailsRaltegravir
Strength:
100mg, 400 mg, 600mg
Form: Tablets
Reference Brands: Isentress (USA/EU)
View DetailsUsually answered within 48 hours | GMP documents shared before you commit